-
Danish 'ghetto' tenants hope for EU discrimination win
-
Cricket Australia boss slams technology as Snicko confusion continues
-
Conway and Latham's 323-run opening stand batters hapless West Indies
-
Alleged Bondi shooters holed up in hotel for most of Philippines visit
-
Japan govt sued over 'unconstitutional' climate inaction
-
US approves $11 billion in arms sales to Taiwan: Taipei
-
England battle to save Ashes as Australia rip through top-order
-
Guarded and formal: Pope Leo XIV sets different tone
-
What to know about the EU-Mercosur deal
-
Trump vows economic boom, blames Biden in address to nation
-
Conway 120 as New Zealand in command at 216-0 against West Indies
-
Taiwan eyes fresh diplomatic ties with Honduras
-
ECB set to hold rates but debate swirls over future
-
Asian markets track Wall St lower as AI fears mount
-
EU holds crunch summit on Russian asset plan for Ukraine
-
Australia PM vows to stamp out hatred as nation mourns youngest Bondi Beach victim
-
Australian PM vows hate speech crackdown after Bondi Beach attack
-
Turkmenistan's battle against desert sand
-
Ukraine's Zelensky in Poland for first meeting with nationalist president
-
England in disarray at 59-3 in crunch Test as Lyon, Cummins pounce
-
Japan faces lawsuit over 'unconstitutional' climate inaction
-
Migrants forced to leave Canada after policy change feel 'betrayed'
-
What's next for Venezuela under the US oil blockade?
-
Salvadorans freed with conditional sentence for Bukele protest
-
Brazil Congress passes bill to cut Bolsonaro prison term
-
Cricket Australia boss slams technology 'howler' in Ashes Test
-
New Zealand 83-0 at lunch on day one of third West Indies Test
-
Ecuadorean footballer Mario Pineida shot and killed
-
US government admits liability in deadly DC air collision
-
SolePursuit Capital Syndicate Establishes Strategic Coordination Office and Appoints Laurence Kingsley as Head
-
1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth
-
Ex-podcaster Dan Bongino stepping down as deputy FBI director
-
Real Madrid scrape past third-tier Talavera in Spanish Cup
-
Hunt for US college mass shooter drags into fifth day
-
Cherki inspires Man City, Newcastle strike late to reach League Cup semis
-
Barcelona, Lyon and Chelsea reach Women's Champions League quarters
-
Venezuela reacts defiantly to US oil blockade, claims exports unaffected
-
Nasdaq tumbles on renewed angst over AI building boom
-
S.Africa expels Kenyans working on US Afrikaner 'refugee' applications
-
US Congress ends Syria sanctions
-
Cherki inspires Man City cruise into League Cup semis
-
Billionaire Trump nominee confirmed to lead NASA amid Moon race
-
Mahomes undergoes surgery, could return for 2026 opener: Chiefs
-
Melania Trump steps into spotlight in Amazon film trailer
-
Brazil Senate advances bill that could cut Bolsonaro jail term
-
Safonov hero as PSG beat Flamengo in Intercontinental Cup
-
Oscars to stream exclusively on YouTube from 2029
-
Oscars to stream exclusively on YouTube from 2029: Academy
-
CNN's future unclear as Trump applies pressure
-
Brazil threatens to walk if EU delays Mercosur deal
| SCS | 0.12% | 16.14 | $ | |
| RBGPF | -2.23% | 80.22 | $ | |
| CMSD | -0.43% | 23.28 | $ | |
| NGG | 1.8% | 77.16 | $ | |
| BCC | 0.59% | 76.29 | $ | |
| RIO | 1.55% | 77.19 | $ | |
| CMSC | -0.34% | 23.26 | $ | |
| GSK | -0.14% | 48.71 | $ | |
| AZN | -1.66% | 89.86 | $ | |
| BCE | -0.78% | 23.15 | $ | |
| BTI | -0.21% | 57.17 | $ | |
| RELX | -0.64% | 40.56 | $ | |
| JRI | -0.6% | 13.43 | $ | |
| RYCEF | 1.48% | 14.86 | $ | |
| BP | 2.06% | 34.47 | $ | |
| VOD | 0.86% | 12.81 | $ |
CEO of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price
TAMPA, FLORIDA / ACCESS Newswire / April 15, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that it has entered into an amendment to the Membership Interest Purchase Agreement with Wellgistics LLC and Wellgistics LLC's former owners to convert a significant cash payment owed by the Company into shares of the Company's common stock at the initial public offering price of $4.50 per share. Specifically, the Company has converted $1.5 million in debt that the Company owed to a seller entity controlled by Brian Norton, its Chief Executive Officer, and that the Company would have needed to pay by June 14, 2025. The $1.5 million in debt was converted into 333,333 shares of the Company's common stock.
This conversion reflects Mr. Norton's deep belief in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Norton's belief in the Company's long-term success, the 333,333 newly issued shares of the Company's common stock are subject to a 12-month lock-up agreement, whereby Mr. Norton is prohibited, except in certain limited exceptions, from selling or transferring such shares.
"I believe we are just getting started at Wellgistics Health," said Brian Norton. "This conversion is a public statement of my unwavering belief in our team, our mission, and the transformative impact we will have on the future of healthcare."
About Wellgistics Health, Inc.
Wellgistics Health, Inc. (NASDAQ:WGRX) is a holding company for existing and future planned operating companies centered around healthcare technology and pharmaceutical services. It seeks to be a micro health ecosystem, with a portfolio of companies consisting of a technology platform, pharmacy, and wholesale operations that provide novel prescription hub and clinical services. The Company is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, the Company intends to shift the dynamic of pharmaceutical care to revolve around the patient for a wide range of therapeutic conditions by offering a full spectrum of integrated solutions as a result of leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from "specialty-lite" to general maintenance conditions. For more information, please visit the Company's website: https://wellgisticshealth.com/.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may", "will", "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please visit:
[email protected]
SOURCE: Wellgistics Health, Inc.
View the original press release on ACCESS Newswire
A.Clark--AT